# Cannabinoids for MS Spasticity: What 27 Randomized Trials Show > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoids-ms-spasticity-randomized-review/ > **Published:** 2026-08-03T23:26:27-04:00 | **Last Modified / Clinically Audited:** 2026-10-22T13:36:13-04:00 > **Clinical Summary:** Across 27 randomized trials, cannabinoids showed modest patient-reported benefit for MS spasticity with low certainty and weak objective change. --- CED Clinical Relevance #90 Cannabis Science Evidence Report A newly published systematic review and network meta-analysis synthesizes 27 randomized trials with more than 3,000 participants. It is highly relevant to patient care, while low certainty, heterogeneous interventions, and limited objective benefit require cautious interpretation. Clinical Insight | CED Clinic A new systematic review of randomized [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) found that cannabinoid interventions, especially THC:CBD extracts, produced modest improvement in patient-reported multiple-sclerosis spasticity compared with placebo. The signal did not translate into equally convincing objective benefit, certainty was low, and the included products and methods varied substantially. Adverse events were frequent, although most were mild to moderate and serious events were rare. For an individual patient, the useful question is whether a defined formulation improves a defined symptom or functional goal enough to outweigh impairment, balance, interaction, and tolerability concerns. The clinically responsible reading is adjunctive and monitored, not a blanket treatment endorsement. Multiple SclerosisSpasticityTHC:CBDSystematic ReviewRandomized Trials Audience People living with multiple sclerosis, caregivers, neurologists, rehabilitation clinicians, and cannabis-science readers Primary Topic cannabinoids for multiple sclerosis spasticity Source [Read the full source](https://pubmed.ncbi.nlm.nih.gov/42543771/) An August 2, 2026 systematic review included 27 randomized trials and more than 3,000 participants. THC:CBD extracts showed a modest patient-reported spasticity benefit versus placebo, but certainty was low, objective benefits were limited, and adverse events were frequent. What This Study Teaches Us Across a heterogeneous randomized evidence base, THC:CBD extracts had the most consistent patient-reported signal. The pooled mean difference was modest, and the review’s low-certainty rating limits confidence about the size and generalizability of benefit. Why This Matters Spasticity can affect sleep, mobility, pain, caregiving, and quality of life in multiple sclerosis. A review that separates subjective symptom change, objective outcomes, formulation differences, and adverse events can improve counseling beyond a simple claim that cannabis either works or does not. Study Snapshot Study Type Systematic review, pairwise random-effects meta-analysis, and Bayesian network meta-analysis of randomized [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) Population More than 3,000 participants with multiple-sclerosis-related spasticity across 27 trials Interventions THC:CBD extracts, other cannabis extracts, isolated natural or synthetic cannabinoids, and smoked cannabis Search Date PubMed, EMBASE, and LILACS searched through December 2, 2025 Risk of Bias Two reviewers used the Cochrane RoB 2 tool Certainty Methods GRADE and CINeMA Pairwise Evidence Seven studies contributed to the reported THC:CBD versus placebo meta-analysis Patient-Reported Result Mean difference -0.82; 95% CI -1.24 to -0.40; I-squared 53% Network Result Mean difference -0.80; 95% credible interval -1.61 to -0.32 Safety Adverse events were frequent and mostly mild to moderate; serious events were rare Certainty Low Major Limitation Substantial clinical and methodological heterogeneity with limited objective benefits Journal British Journal of Clinical Pharmacology Electronic Publication August 2, 2026 Authors Leticia Hamm-Buiar, Daniela Gorski, Marcela Harumi Kagueiama, and Astrid Wiens PMID / DOI 42543771 / 10.1002/bcp.70719 Clinical Bottom Line Cannabinoids, particularly THC:CBD extracts, may provide modest patient-reported relief of MS spasticity for some patients. Low certainty, heterogeneous evidence, limited objective benefit, and frequent adverse events support cautious adjunctive use with monitoring rather than routine or universal treatment. What the Review Included The authors searched three databases and included randomized trials evaluating natural or synthetic cannabinoids for MS-related spasticity. Twenty-seven studies with more than 3,000 participants entered the qualitative synthesis. The interventions were not interchangeable. They included THC:CBD extracts, other cannabis extracts, isolated cannabinoids, synthetic cannabinoids, and smoked cannabis. What the Pooled Results Found In the seven-study pairwise analysis, THC:CBD extracts reduced patient-reported spasticity versus placebo by a mean difference of 0.82 points in the favorable direction. The 95% confidence interval ranged from 0.40 to 1.24 points. The Bayesian network analysis also favored THC:CBD extracts, with a mean difference of 0.80 points. These estimates indicate a modest average effect, not elimination of spasticity. Why Patient-Reported and Objective Outcomes Differ Spasticity has both experienced and examiner-measured dimensions. A person may notice less tightness, fewer spasms, or easier daily activity even when an objective scale changes little. That difference can be clinically meaningful, but it also makes blinding, expectations, scale selection, and the minimum important change especially relevant when interpreting cannabinoid trials. Safety Belongs in the Main Result Adverse events were frequent, although most were described as mild to moderate and serious events were rare. The abstract does not provide product-specific event rates, so the review should not be used to claim that every formulation has the same safety profile. Sedation, dizziness, cognitive effects, balance, driving, falls, medication interactions, dose, THC exposure, and individual vulnerability remain practical monitoring considerations. How to Use the Finding Clinically The authors describe cannabinoids as a cautious adjunctive option, not a replacement for established spasticity management. A clinical discussion should define the target symptom, prior treatments, formulation, dose, expected time course, and stopping criteria. Monitoring should ask whether any subjective improvement produces meaningful gains in function, sleep, comfort, or care burden without unacceptable adverse effects. How Strong Is This Evidence? The review restricts the efficacy synthesis to randomized clinical trials, includes more than 3,000 participants, uses duplicate review, RoB 2, GRADE, CINeMA, pairwise meta-analysis, and a network meta-analysis. These methods provide a stronger foundation than a narrative review or uncontrolled case series. Where This Paper Deserves Skepticism The certainty rating was low, interventions and methods were heterogeneous, the key pairwise estimate came from seven studies rather than all 27, and patient-reported improvement was more persuasive than objective benefit. Average effects may conceal substantial differences by product, dose, trial design, and patient response. What This Paper Does Not Show The review does not prove that every cannabis product improves spasticity, establish superiority over all standard therapies, define an ideal THC:CBD ratio or dose, identify which patients will respond, demonstrate large objective functional gains, or establish long-term safety. How This Fits With the Broader Clinical Conversation Earlier reviews have also suggested modest cannabinoid effects for MS spasticity, but conclusions vary with included trials, formulations, outcome scales, and duration. This review adds a new 27-trial randomized synthesis and network comparison while retaining a low-certainty conclusion. The next useful evidence would link standardized formulations and doses to patient-important outcomes such as mobility, transfers, sleep, pain, caregiver burden, falls, cognition, and durable treatment continuation. Bladder symptoms are a separate question; see [what the trials show for MS bladder symptoms](https://cedclinic.com/cannabis-ms-bladder-symptoms-evidence/). Dr. Caplan’s Take *This review supports a careful therapeutic trial for selected patients more than it supports a broad declaration that cannabinoids treat MS spasticity.* *The clinical question is whether a defined product at a defined dose improves a defined patient goal enough to justify adverse effects and complexity. Subjective relief matters, but it should be connected to function and monitored over time.* What a Careful Reader Should Take Away Retain both halves of the finding: a modest patient-reported signal is present, especially for THC:CBD extracts, and confidence remains limited because objective benefits were smaller, adverse events were frequent, and certainty was low. Evidence Interpretation Guide Table of Contents - [How to Interpret the MS Spasticity Review](#How_to_Interpret_the_MS_Spasticity_Review)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Modest Relief May Still Matter](#Modest_Relief_May_Still_Matter) - [Use a Structured Therapeutic Trial](#Use_a_Structured_Therapeutic_Trial) - [Low Certainty Limits Confidence](#Low_Certainty_Limits_Confidence) - [Subjective and Objective Measures Diverged](#Subjective_and_Objective_Measures_Diverged) - [A Broader Randomized Synthesis](#A_Broader_Randomized_Synthesis) - [Product Specificity Matters](#Product_Specificity_Matters) - [Measure Function and Durability](#Measure_Function_and_Durability) - [Access Needs Evidence-Literate Counseling](#Access_Needs_Evidence-Literate_Counseling) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret the MS Spasticity Review A systematic review can strengthen an evidence signal without making it certain. Four checks keep this result clinically proportionate. ### A Four-Step Reading Frame **Start with certainty**Randomized trials are valuable, but the authors still rated the combined evidence as low certainty. **Separate outcome types**Patient-reported spasticity improved more consistently than objective measures. **Keep products distinct**THC:CBD extracts, isolated cannabinoids, synthetic agents, and smoked cannabis should not be treated as one intervention. **Connect benefit to burden**A modest symptom change matters only when it improves a patient goal without unacceptable adverse effects. The Research Question How effective and safe are cannabinoid interventions for multiple-sclerosis-related spasticity in randomized trials? The Patient Question Could a monitored cannabinoid trial help my spasticity enough to improve daily life? The Bottom Line The review supports cautious adjunctive consideration, not universal treatment. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview Eight perspectives translate the new randomized-evidence synthesis without turning modest, low-certainty improvement into treatment proof. #### Modest Relief May Still Matter Some patients reported less spasticity with THC:CBD extracts than with placebo. Ask whether any change improves sleep, transfers, walking, comfort, or another personal goal. Lens takeaway Define what meaningful improvement would look like for you. #### Use a Structured Therapeutic Trial Select a defined formulation, starting plan, target outcome, and review interval. Monitor cognition, balance, sedation, interactions, and functional response alongside symptom ratings. Lens takeaway A monitored trial is more defensible than open-ended use. #### Low Certainty Limits Confidence Twenty-seven randomized trials sound definitive, but heterogeneity and bias can weaken pooled conclusions. The principal pairwise estimate included seven studies and showed a modest average effect. Lens takeaway Study count is not the same as certainty. #### Subjective and Objective Measures Diverged Patient experience deserves attention, especially for symptoms that are difficult to measure. Greater subjective than objective benefit also makes expectancy, blinding, and scale interpretation important. Lens takeaway Read both outcome types together. #### A Broader Randomized Synthesis Earlier CED coverage examined a nine-trial meta-analysis and a separate review of symptoms beyond spasticity. This paper combines 27 randomized trials focused on spasticity efficacy and safety and adds network comparison. Lens takeaway The new contribution is broader randomized synthesis, not a wholly new treatment claim. #### Product Specificity Matters Cannabinoid content, route, dose, timing, and [product quality](https://cedclinic.com/cbd-gummies-chronic-pain/) can change both benefit and risk. Do not generalize a THC:CBD extract signal to every dispensary or hemp product. Lens takeaway Match the evidence to the actual formulation. #### Measure Function and Durability Future trials should standardize products and report clinically important change thresholds. Longer follow-up should connect symptom change with mobility, sleep, falls, cognition, and continuation. Lens takeaway Better trials need patient-important outcomes. #### Access Needs Evidence-Literate Counseling Availability alone does not tell patients which formulation or dose matches the evidence. Clear labeling and clinically usable product information are necessary for responsible monitoring. Lens takeaway Access and evidence quality should advance together. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabinoids+for+MS+Spasticity%3A+What+27+Randomized+Trials+Show&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-ms-spasticity-randomized-review%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-ms-spasticity-randomized-review%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabinoids+for+MS+Spasticity%3A+What+27+Randomized+Trials+Show%20https%3A%2F%2Fcedclinic.com%2Fcannabinoids-ms-spasticity-randomized-review%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials.](https://pubmed.ncbi.nlm.nih.gov/42543771/) Related Reading at CED Clinic Continue exploring the evidence [Long-Term Cannabis Therapy May Change MS Spasticity Outcomes](https://cedclinic.com/cannabis-for-ms-spasticity-meta-analysis-2026/) Earlier coverage of a nine-trial meta-analysis, useful for comparing duration-related findings with the new broader randomized synthesis. [Compare the earlier meta-analysis](https://cedclinic.com/cannabis-for-ms-spasticity-meta-analysis-2026/) [Nabiximols for MS: What a New Meta-Analysis Shows Beyond Spasticity](https://cedclinic.com/nabiximols-multiple-sclerosis-beyond-spasticity-meta-analysis/) A separate evidence synthesis focused on sleep, bladder function, gait, and other outcomes beyond the core spasticity question. [Review symptoms beyond spasticity](https://cedclinic.com/nabiximols-multiple-sclerosis-beyond-spasticity-meta-analysis/) [Medical Cannabis Beyond Pain: PM&R Review on Spasticity, Seizures, Sleep & Nausea](https://cedclinic.com/medical-cannabis-non-pain-indications-pmr-review/) Rehabilitation context for separating symptom relief from objective function and considering sedation, falls, and monitoring. [Read the rehabilitation context](https://cedclinic.com/medical-cannabis-non-pain-indications-pmr-review/) Similar Studies on CEDClinic.com Earlier coverage on closely related evidence When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved. Related digest item [Medical Cannabis Beyond Pain: PM&R Review on Spasticity, Seizures, Sleep & Nausea](https://cedclinic.com/medical-cannabis-non-pain-indications-pmr-review/) A PM&R-focused narrative review examines [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) non-pain indications including spasticity, seizures, sleep disturbances, and chemotherapy-induced nausea. While patient-reported symptom benefits are noted, evid… Covers a closely related topic; this CED post is older by about 3 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/medical-cannabis-non-pain-indications-pmr-review/) Related digest item [Nabiximols for MS: What a New Meta-Analysis Shows Beyond Spasticity](https://cedclinic.com/nabiximols-multiple-sclerosis-beyond-spasticity-meta-analysis/) nabiximols multiple sclerosis: A June 25, 2026 meta-analysis pooling 2,949 multiple sclerosis patients found nabiximols linked to significant improvement in bladder function, sleep disruption, spasm quality, and gait be… Covers a closely related topic; this CED post is older by about 5 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/nabiximols-multiple-sclerosis-beyond-spasticity-meta-analysis/) Related digest item [Cannabinoid Immune Modulation and Autoimmune Disease: A Literature Review](https://cedclinic.com/cannabinoid-immune-modulation-autoimmune-disease-review/) This literature review examines cannabinoid immune modulation and its potential impact on autoimmune disease. It highlights [CB2 receptor](https://cedclinic.com/s-caryophyllene-a-terpine-found-in-cannabis-demonstrates-therapeutic-potential-in-a-mouse-model-of-ms/) biology and laboratory evidence while noting the scarcity of controlled clinical t… Covers a closely related topic; this CED post is older by about 13 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/cannabinoid-immune-modulation-autoimmune-disease-review/) Related digest item [Long-Term Cannabis Therapy May Change MS Spasticity Outcomes](https://cedclinic.com/cannabis-for-ms-spasticity-meta-analysis-2026/) Cannabis for MS spasticity was associated with meaningful symptom improvement in a new meta-analysis involving 2,544 multiple sclerosis patients across nine trials. The strongest benefits emerged with longer treatment d… Covers a closely related topic; this CED post is older by about 85 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/cannabis-for-ms-spasticity-meta-analysis-2026/) Related digest item [France’s Medical Cannabis Trial: 3% Serious Adverse Events in 3,164 Patients Over Three Years](https://cedclinic.com/medical-cannabis-safety-adverse-drug-reactions-france/) The medical [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/) adverse drug reactions study in France tracked 3,164 patients over three years. It found 3% experienced serious adverse drug reactions, mainly neurological, gastrointestinal, and psychiatric…. Covers a closely related topic; this CED post is older by about 95 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/medical-cannabis-safety-adverse-drug-reactions-france/) Related digest item [What the DOJ Cannabis Order Means for Patients and Clinicians](https://cedclinic.com/medical-cannabis-schedule-iii-order/) The [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) Schedule III order is a major federal policy change, but it is not the same as new clinical proof. This Evidence Watch explains what the DOJ action may mean for research access, patient care, and re… Covers a closely related topic; this CED post is older by about 100 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/medical-cannabis-schedule-iii-order/) Related digest item [Cannabinoids Offer Modest Pain Relief but Fall Short of First-Line Status, Review Concludes](https://cedclinic.com/cannabinoid-analgesia-review-chronic-pain-2025/) This cannabinoid analgesia review highlights modest, condition-specific pain relief from cannabinoids. Safety concerns and regulatory challenges limit their use to adjunctive therapy. Patients unresponsive to convention… Covers a closely related topic; this CED post is older by about 108 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/cannabinoid-analgesia-review-chronic-pain-2025/) Related digest item [Cannabinoids Show Promise for Chronic Pain, But Evidence Remains Thin](https://cedclinic.com/cannabinoids-chronic-pain-evidence-review/) The cannabinoids [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) evidence review reveals moderate efficacy signals across several conditions but highlights the low quality of current studies. While cannabinoids show promise, the evidence remains thin due… Covers a closely related topic; this CED post is older by about 115 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/cannabinoids-chronic-pain-evidence-review/) Related digest item [Medical Cannabis for Chronic Pain: Promise, Pharmacology, and Persistent Gaps](https://cedclinic.com/medical-cannabis-chronic-pain-review-2025/) This 2025 [medical cannabis](https://cedclinic.com/cbd-gummies-memory-effects-evidence-practical/) [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/) review examines the pharmacology and clinical evidence for cannabinoids in pain management. While promising, significant gaps remain in standardized dosing and long-term safety da… Covers a closely related topic; this CED post is older by about 115 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/medical-cannabis-chronic-pain-review-2025/) Related digest item [Research Limits on Knowledge of Benefit or Harm of Cannabis and Cannabinoids Use](https://cedclinic.com/research-limits-cannabis-benefits-harms/) Research limits on cannabis benefits highlight significant gaps in clinical evidence and safety data. Clinicians face uncertainty when recommending cannabinoids due to insufficient randomized controlled trials. Understa… Covers a closely related topic; this CED post is older by about 124 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/research-limits-cannabis-benefits-harms/) ## Frequently Asked Questions How many randomized trials were included? The systematic review included 27 randomized trials with more than 3,000 participants in its qualitative synthesis. What cannabinoid treatment had the clearest signal? THC:CBD extracts had the most consistent patient-reported spasticity benefit compared with placebo. How large was the reported benefit? The pairwise meta-analysis reported a mean difference of 0.82 points in the favorable direction, which the authors interpreted as modest. Did objective spasticity measures improve as clearly? No. The review reported limited objective benefits compared with the patient-reported signal. How certain is the evidence? The authors rated the certainty as low because of clinical and methodological heterogeneity and other limitations. Were adverse events reported? Yes. Adverse events were frequent but mostly mild to moderate, while serious events were rare in the review’s summary. Does this apply to every cannabis product? No. The trials used different extracts, isolated or synthetic cannabinoids, and smoked cannabis, so the findings cannot validate every product. Should cannabinoids replace standard spasticity treatment? The review supports cautious adjunctive consideration, not replacement of established treatment or individualized neurologic care. What should clinicians monitor? Monitoring can include the target symptom, function, sleep, cognition, balance, sedation, interactions, adverse effects, and whether benefit persists. What is the practical takeaway? A defined and monitored cannabinoid trial may be reasonable for selected patients, but modest benefit and low certainty should guide expectations. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).